These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 10639353)

  • 1. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.
    Pfeltz RF; Singh VK; Schmidt JL; Batten MA; Baranyk CS; Nadakavukaren MJ; Jayaswal RK; Wilkinson BJ
    Antimicrob Agents Chemother; 2000 Feb; 44(2):294-303. PubMed ID: 10639353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.
    Koehl JL; Muthaiyan A; Jayaswal RK; Ehlert K; Labischinski H; Wilkinson BJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3749-57. PubMed ID: 15388430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate.
    Boyle-Vavra S; Carey RB; Daum RS
    J Antimicrob Chemother; 2001 Nov; 48(5):617-25. PubMed ID: 11679550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.
    Boyle-Vavra S; Berke SK; Lee JC; Daum RS
    Antimicrob Agents Chemother; 2000 Feb; 44(2):272-7. PubMed ID: 10639349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function.
    Sakoulas G; Eliopoulos GM; Fowler VG; Moellering RC; Novick RP; Lucindo N; Yeaman MR; Bayer AS
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2687-92. PubMed ID: 15980337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.
    Cui L; Ma X; Sato K; Okuma K; Tenover FC; Mamizuka EM; Gemmell CG; Kim MN; Ploy MC; El-Solh N; Ferraz V; Hiramatsu K
    J Clin Microbiol; 2003 Jan; 41(1):5-14. PubMed ID: 12517819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.
    Hubert SK; Mohammed JM; Fridkin SK; Gaynes RP; McGowan JE; Tenover FC
    J Clin Microbiol; 1999 Nov; 37(11):3590-3. PubMed ID: 10523558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50.
    Utaida S; Pfeltz RF; Jayaswal RK; Wilkinson BJ
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1541-5. PubMed ID: 16569879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
    Sakoulas G; Eliopoulos GM; Moellering RC; Wennersten C; Venkataraman L; Novick RP; Gold HS
    Antimicrob Agents Chemother; 2002 May; 46(5):1492-502. PubMed ID: 11959587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates.
    Wootton M; MacGowan AP; Walsh TR
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4195-7. PubMed ID: 17043121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.
    Yusof A; Engelhardt A; Karlsson A; Bylund L; Vidh P; Mills K; Wootton M; Walsh TR
    J Clin Microbiol; 2008 Sep; 46(9):3042-7. PubMed ID: 18596146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.
    Cui L; Lian JQ; Neoh HM; Reyes E; Hiramatsu K
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3404-13. PubMed ID: 16048954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
    Kusuma CM; Kokai-Kun JF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The VISA/GISA problem: therapeutic implications.
    Liñares J
    Clin Microbiol Infect; 2001; 7 Suppl 4():8-15. PubMed ID: 11688538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains.
    Wootton M; Bennett PM; MacGowan AP; Walsh TR
    J Antimicrob Chemother; 2005 Nov; 56(5):944-7. PubMed ID: 16157619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals.
    Cartolano GL; Cheron M; Benabid D; Leneveu M; Boisivon A;
    Clin Microbiol Infect; 2004 May; 10(5):448-51. PubMed ID: 15113324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus.
    Adhikari RP; Scales GC; Kobayashi K; Smith JM; Berger-Bächi B; Cook GM
    J Antimicrob Chemother; 2004 Aug; 54(2):360-3. PubMed ID: 15243027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals.
    Nonhoff C; Denis O; Struelens MJ
    Clin Microbiol Infect; 2005 Mar; 11(3):214-20. PubMed ID: 15715719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.
    Saito M; Katayama Y; Hishinuma T; Iwamoto A; Aiba Y; Kuwahara-Arai K; Cui L; Matsuo M; Aritaka N; Hiramatsu K
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5024-35. PubMed ID: 24841271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.